Committee:New York City Society of Health-system Pharmacists  
**Topic: Pharmacists’ involvement in the development and management of drug diversion surveillance processes to promote patient care and health-system compliance**Sponsors: Amisha Leimbach, PharmD, CJCP, Maabo Kludze, PharmD, MBA, BCPS, CDE, Jamie Chin, PharmD, MS, BCOP

Whereas, approximately 10% of health-care workers may be involved in controlled substance diversion at some point in their career, which can lead to serious patient safety issues, harm to the diverter, and significant liability risk to the organization1

Whereas, the American Society of Health-System Pharmacists has developed a guideline to recommend developing a controlled substance diversion prevention strategy and framework for integrating strategies into a comprehensive organization program1

Whereas, pharmacist involvement in the development of a multidisciplinary drug diversion committee will provide insight into how controlled substances are procured, prepared, dispensed, stored on patient care units, and wasted, to develop best practices and create proper documentation and follow-up in a drug diversion response team in response to incidences that have occurred

Whereas, an interdisciplinary team, in which pharmacists, participate in the development of a policy and/or procedure that ensures compliance with legal and regulatory requirements

Resolved That:

The New York State Council of Health-system Pharmacists supports the involvement of pharmacists in the development of a process for drug diversion surveillance to promote patient safety and health-system compliance with regulatory requirements.

Date: November 7, 2019

By: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Amisha Leimbach, PharmD, CJCP

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Maabo Kludze, PharmD, MBA, BCPS, CDE

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Jamie Chin, MS, PharmD, BCOP

References

1. American Society of Health-System Pharmacists. ASHP guidelines on preventing diversion of controlled substances. Am J Health-Syst Pharm. 2017; 74: 325-48.
2. Barnhart T. A Million Little Pieces: Developing a Controlled Substance Diversion Program. HealthPartners Regional Hospital.
3. Rohman C. Roads to recovery: Drug diversion surveillance programs. Nursing Management: 2012; 43: 28-31.